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Mini-Symposium
Pain and Poppies: The Good, the Bad, and the Ugly of Opioid
Analgesics
Tuan Trang,1,2 Ream Al-Hasani,3,4Daniela Salvemini,5Michael W. Salter,6Howard Gutstein,7 and XCatherine M. Cahill8
Departments of 1Comparative Biology and Experimental Medicine and 2Physiology and Pharmacology, Hotchkiss Brain Institute, University of Calgary,
Calgary, Alberta T2N 4N1, Canada, Departments of 3Anesthesiology and 4Anatomy–Neurobiology, Washington University School of Medicine, St. Louis,
Missouri 63110, 5Department of Pharmacological and Physiological Science, St. Louis University School of Medicine, St. Louis, Missouri 63104,
6Neurosciences and Mental Health Program, Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada, 7MD Anderson Cancer Center, Houston, Texas
77030, and 8Department of Anaesthesiology and Perioperative Care, University of California Irvine, Irvine, California 92697
Treating pain is one of the most difficult challenges in medicine and a key facet of disease management. The isolation of morphine by
Friedrich Sertu¨rner in 1804 added an essential pharmacological tool in the treatment of pain and spawned the discovery of a new class of
drugs known collectively as opioid analgesics. Revered for their potent pain-relieving effects, evenMorpheus the god of dreams could not
have dreamt that his opium tincture would be both a gift and a burden to humankind. To date, morphine and other opioids remain
essential analgesics for alleviating pain. However, their use is plagued by major side effects, such as analgesic tolerance (diminished
pain-relieving effects), hyperalgesia (increased pain sensitivity), and drug dependence. This review highlights recent advances in under-
standing the key causes of these adverse effects and explores the effect of chronic pain on opioid reward.
Opioids and pain: scope of the problem
It is estimated that 20–30% of Americans suffer from chronic
pain, which is similar to that reported in Canada, Australia, and
European countries (Blyth et al., 2001; Breivik et al., 2006; Jo-
hannes et al., 2010; Schopflocher et al., 2011). Equally striking is
that chronic pain is among the most common forms of chronic
illness afflicting individuals younger than 60 years of age
(O’Connor, 2009). Chronic pain is also amajor cause of disability
(Manchikanti et al., 2013), and it is the cardinal feature of a
diverse spectrum of diseases, including arthritis, migraine, can-
cer,metabolic disorders, andneuropathies. Treating pain in these
diseases is notoriously difficult and often requires opioids, the
most potent class of drugs used for controlling pain. Opioids are
particularly effective for treating acute moderate-to-severe pain
after surgery or trauma, and they are quintessential drugs in a
physician’s pharmacological toolbox for managing chronic pain.
In 2012, physicians in the United States wrote259 million opi-
oid prescriptions, which equates to one bottle of pills for every
adult American (according to the Centers for Disease Control
and Prevention). Consumption of prescription opioids is highest
in the United States and Canada, and, in these countries, opioid
use for managing pain continues to grow (Gomes et al., 2014).
Long-term opioid exposure can result in the development of an-
algesic tolerance, the hallmark feature of which is a loss in pain-
Received July 16, 2015; revised Aug. 12, 2015; accepted Aug. 13, 2015.
Thiswork is supportedby Canadian Institutes ofHealth ResearchGrantsMOP133523 (T.T.),MOP123298 (C.M.C.),
andMOP123307 (M.W.S.), Natural Sciences and Engineering Research Council of Canada Grant RGPIN418299 (T.T.),
the Rita Allen Foundation (T.T), the American Pain Society (T.T.), the Canada Research Chair Program (M.W.S.), the
Anne and Max Tanenbaum Chair Program (M.W.S.), National Institutes of Health Grants R01 CA169519 (D.S.) and
R21 DA040305 (D.S.), the National Institute on Drug Abuse Grant 1RO1DA036680-01 (H.B.G.), Cancer Prevention
andResearch Institute of Texas Individual Investigator ResearchAwardRP120408 (H.B.G.), andNational Institute on
Drug Abuse K99/R00 Pathway to Independence Award DA038725 (R.A.-H.). We thank Churmy Fan for assistance
with figure illustrations.
Correspondence should be addressed to either of the following: Dr. Tuan Trang, Departments of Comparative
Biology and Experimental Medicine, and Physiology and Pharmacology, Hotchkiss Brain Institute, University of
Calgary, 3330 Hospital Drive, Calgary, Alberta T2N 4N1, Canada, E-mail: trangt@ucalgary.ca; or Dr. Catherine Cahill,
Department of Anaesthesiology and Perioperative Care, University of California Irvine, Irvine, California 92697,
E-mail: cmcahill@uci.edu.
DOI:10.1523/JNEUROSCI.2711-15.2015
Copyright © 2015 the authors 0270-6474/15/3513879-10$15.00/0
Significance Statement
Chronic pain is pervasive and afflicts100millionAmericans. Treating pain in these individuals is notoriously difficult and often
requires opioids, one of themost powerful and effective classes of drugs used for controlling pain.However, their use is plaguedby
major side effects, such as a loss of pain-relieving effects (analgesic tolerance), paradoxical pain (hyperalgesia), and addiction.
Despite the potential side effects, opioids remain the pharmacological cornerstone ofmodernpain therapy. This reviewhighlights
recent breakthroughs in understanding the key causes of these adverse effects and explores the cellular control of opioid systems
in reward and aversion. The findings will challenge traditional views of the good, the bad, and the ugly of opioids.
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relieving effect. In an effort to overcome tolerance, current
strategies involve the use of either higher (and more frequent)
doses of opioids or switching to more potent opioid agonists.
However, these strategies have limited success because tolerance
often reestablishes over time, leaving patients without adequate
pain control. The need for escalating amounts of opioids puts
patients at risk of severe sides effects, including dependence and
respiratory distress. In theUnited States, an estimated 2.1million
Americans suffer fromopioid substance use disorders (according
to the National Institute of Drug Abuse), and 44 deaths a day are
attributed to opioid overdose (according to the Centers for Dis-
ease Control and Prevention). There is also a higher incidence of
opioid prescription medication addiction that has led to an in-
crease in heroin use and a nearly quadrupling of death rate from
overdose between 2002 and 2013 (Okie, 2010). Prescription, di-
version, and illicit use of opioid therapeutics have emerged as
major societal concerns in recent years (Compton and Volkow,
2006; SAMHSA, 2011). Although the effect of opioid tolerance
and dependence has gained considerable attention, the problem
of opioid-induced hyperalgesia—characterized by a paradoxical
increase in pain sensitivity—is a less recognized consequence of
opioid use. Despite the serious side effects that hinder long-term
opioid use, there remains a strong reliance on this class of drugs
for pain management. Therefore, it is imperative that we under-
stand the underlying causes of these adverse effects to improve
the utility of opioids in treating pain. In this review, we focused
our efforts on critically evaluating the evidence that platelet-
derived growth factor receptor- (PDGFR-), adenosine, and
microglia are key cellular substrates in opioid analgesic tolerance,
hyperalgesia, and neuropathic pain. We also present emerging
evidence that chronic pain fundamentally alters reward circuitry,
which has direct implications for the ability of opioids to alleviate
the emotional component of pain and for their abuse potential.
This article is a summary of topics covered in amini-symposium.
For a more comprehensive review of the subject, the reader is
referred to other articles on this topic (Marchand et al., 2005;
Beggs et al., 2012; Williams et al., 2013; Bourinet et al., 2014;
Cahill et al., 2014; Grace et al., 2014; Fields and Margolis, 2015;
Me´lik Parsadaniantz et al., 2015).
Opioid receptors, analgesia, and the CNS
Opioids exert their effects through interaction with the super-
family of G-protein-coupled opioid receptors: , , and . All
three receptor subtypes share extensive structural homology and
couple to pertussis toxin-sensitive guanine nucleotide binding
Gi/o-proteins to inhibit adenylyl cyclase, activate potassium con-
ductance, suppress calcium conductance, and inhibit neu-
rotransmitter release (Feng et al., 2012). Opioid receptors are
expressed throughout the CNS and PNS on key nodes within the
pain pathway. In theCNS, opioid receptors are highly localized in
subcortical regions of the brain (thalamus, periaqueductal gray,
rostral ventromedial medulla, and locus ceruleus) from which
descending pain-modulating pathways originate and in the dor-
sal horn region of the spinal cord, an area important for the relay
of nociceptive input to the brain and a primary site of action for
the analgesic effects of opioids (Fields, 2004; Fig. 1). In the spinal
dorsal horn, opioid receptors are expressed primarily in laminae
I and II, with the proportion of , , and  receptors comprising
70, 20, and 10%, respectively (Gouarde`res et al., 1985;Morris and
Herz, 1987; Stevens et al., 1991). These receptors are localized on
presynaptic afferent fibers (Lamotte et al., 1976; Gamse et al.,
1979), interneurons (Kemp et al., 1996), and postsynaptic pro-
jection neurons (Zieglga¨nsberger and Bayerl, 1976). Additional
opioid-like receptors have been identified in the CNS, including
the opioid receptor like-1 (ORL-1) receptor (Meunier et al., 1995;
Fioravanti and Vanderah, 2008). Unlike classical opioid recep-
tors, theORL-1 receptor is insensitive to naloxone, a nonselective
opioid receptor antagonist. Evidence suggests that opioids can
also bind and activate the toll-like receptor 4 (TLR4), an innate
immune pattern-recognition receptor (Hutchinson et al., 2010;
Jacobsen et al., 2014). The importance of these nonclassical opi-
oid receptors in themodulation of pain and in the negative effects
associated with opioid use is beyond the scope of the current
review (Largent-Milnes and Vanderah, 2010; Pasternak and Pan,
2013; Convertino et al., 2015).
PDGFR-: novel role in opioid tolerance and
neuropathic pain
Opioid receptor activation triggers a complex cascade of signal-
ing events. A major downstream consequence of  receptor sig-
naling is the activation of receptor tyrosine kinases, which are
critically implicated in an array of cellular processes (Lemmon
and Schlessinger, 2010).Wang et al. (2012) discovered recently in
rats that chronic morphine treatment results in the activation of
PDGFR-, a receptor tyrosine kinase that is activated by recep-
tors (Belcheva et al., 2001). Activation of the PDGFR- receptor,
in turn, modulates  receptor function (Belcheva et al., 2001).
Key to their finding was that chronic morphine treatment in-
duced PDGFR- phosphorylation, which was abrogated by ima-
tinib, a Food and Drug Administration-approved inhibitor of
PDGFR used clinically to treat cancer (Wang et al., 2012). Spinal
or subcutaneous administration of imatinib significantly blocked
the development of morphine analgesic tolerance and reversed
established tolerance. Although imatinib prevented tolerance,
when rats were challenged with morphine alone after repeated
doses of morphine and imatinib, the animals were all tolerant to
antinociceptive effects of morphine. This suggests that imatinib
did not directly inhibit the processes that cause tolerance, but
rather it bypassed these cellular adaptations in restoring the an-
algesic effects of morphine. The results indicate that imatinib
could be effective as an adjuvant therapy to limit or reverse mor-
phine analgesic tolerance.
Themechanism responsible formorphine-induced activation
of the PDGFR- was identified to be dependent on the release of
PDGF-B, a selective agonist of the PDGFR- receptor. Rodents
treated with a PDGFR-–Fc chimeric protein, which scavenges
released PDGF-B, suppressed the development of morphine tol-
erance and restored analgesia in morphine tolerant rats, similar
to the actions of imatinib. Conversely, administration of PDGF-B
induced robust tolerance in opioid-naive animals, indicating that
PDGFR- signaling is both necessary and sufficient to cause
morphine analgesic tolerance. However, the importance of
PDGF-B extends beyond morphine tolerance to include a role in
neuropathic pain (pain arising from damage or dysfunction of
the nervous system), which is often refractory to the analgesic
effects of opioids. Donica et al. (2014) reported that morphine,
when administered together with imatinib, reversed mechanical
allodynia in nerve-injured rats, suggesting that this pathway may
be responsible for dysfunction of opioid effects in neuropathic
pain states. In contrast, mechanical allodynia was not affected
when morphine or imatinib was administered alone (Donica et
al., 2014). Collectively, these studies provide the first lines of
evidence that PDGFR- signaling is a critical overlapping mech-
anism in the etiology of morphine tolerance and neuropathic
pain. A major question arising from these studies is, what is the
critical cell type(s) throughwhich PDGFR- signaling gatesmor-
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phine tolerance and neuropathic pain? Moreover, there are
mechanistic similarities between the development of opioid tol-
erance and the occurrence of pain hypersensitivity associated
with nerve injury, such as NMDA receptor phosphorylation and
gliosis (Mao andMayer, 2001;Wen et al., 2011).Whether there is
overlap between these signaling cascades and PDGFR remains
unresolved.
Adenosine, adenosine receptors, and interactions
with opioids
Adenosine is an essential molecular building block for the proto-
typical energy source molecule ATP. However, adenosine in its
own right is an important, biologically active molecule that reg-
ulates neuronal and non-neuronal function in the CNS and PNS.
Released in response to trauma, seizure, inflammation, pain, and
a host of other conditions, adenosine triggers compensatory ho-
meostatic and neuromodulatory responses that protect against
neuronal damage (Cunha, 2001). Extracellular adenosine can be
derived through a series of catalytic steps. First, the cell surface
ectonucleoside triphosphate diphosphohydrolase [cluster of dif-
ferentiation (CD) 39] rapidly hydrolyzes ATP or ADP to AMP,
which is then further broken down by ecto-5-nucleotidase
(CD73) to produce adenosine (Robson et al., 2006; Bonan, 2012).
Another source of adenosine comes from intracellular pools re-
leased by ectonucleoside transporters (ENTs) expressed on neu-
rons and glia (Bonan, 2012). The removal of extracellular
adenosine is controlled by ENT uptake (when extracellular aden-
osine concentration exceeds intracellular concentration), adeno-
sine deaminase deamination, and intracellular phosphorylation
by adenosine kinase (Blackburn and Kellems, 1996; Spychala et
al., 1996; Thorn and Jarvis, 1996; King et al., 2006). It is generally
accepted that adenosine kinase is the “upstream coordinator” of
adenosine receptor (AR) signaling, which is mediated by the P1
family of G-protein-coupled receptors: A1, A2A, A2B, and A3 AR
subtypes (Fredholm et al., 2005, 2011; Boison et al., 2010).
The first clues that adenosine may modulate pain and regu-
late opioid analgesia came from the demonstration that syste-
mic administration of an adenosine analog is antinociceptive
(Vapaatalo et al., 1975) and that methylxanthines (which block
ARs) inhibits morphine analgesia (Ho et al., 1973a,b). Evidence
soon emerged that the spinal cord is a key site of action for aden-
osinemodulation of pain (Post, 1984) and thatmorphine admin-
istration in rats readily evokes the release of adenosine in the
spinal cord (Sweeney et al., 1987). This release has also been
reported in human subjects after intrathecal injection of fentanyl,
a potent receptor agonist (Eisenach et al., 2004). It is now clear
that spinal analgesia produced by adenosine ormorphine admin-
istration depends critically on the adenosine receptor subtype
A1AR (Poon and Sawynok, 1998; Wu et al., 2005; Zhang et al.,
2005). However, adenosine may be playing both the roles of
“good cop” and “bad cop” because its activity has also been im-
plicated in the unwanted side effects associated with chronic opi-
oid use (Ahlijanian and Takemori, 1985; Contreras et al., 1990;
Germany et al., 1990). For example, opioid withdrawal increases
Figure 1. Spinal mechanisms of opioid analgesia. A, In the spinal dorsal horn, nociceptive signals encoded by action potentials trigger the release of nociceptive transmitters, such as substance
P (SP), calcitonin gene-related peptide (CGRP), and L-glutamate (Glu). Second-order projection neurons then relay this information from the spinal cord to the brain, where the information is
disseminated and decoded to produce the emotional and sensory experiences of pain. B, Opioids produce their analgesic effects by inhibiting spinal nociceptive transmission. On presynaptic nerve
terminals, opioids reduce cAMP signaling and suppress activity of voltage-gated calcium channels, which inhibits release of nociceptive transmitters. On postsynaptic neurons, opioids activate
inward potassium channels to cause hyperpolarization of ascending projection neurons. Opioids also produce analgesia by activating descending inputs from the periaqueductal gray (PAG) and
rostral ventromedial medulla (RVM), which are key components of the descending inhibitory pain pathways. In these supraspinal structures, opioid-mediated disinhibition of GABAergic interneu-
rons leads to activation of monoamine-containing descending neurons that suppress nociceptive transmission in the spinal dorsal horn. CGRPR, Calcitonin gene-related peptide receptor; NK-1,
neurokinin-1 receptor.
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adenosine acting at A1AR in the ventral tegmental area (VTA)
and substantia nigra, resulting in an inhibition of GABA release
and thereby altering reward processing (Bonci and Williams,
1996; Shoji et al., 1999; Matsui et al., 2014). Chronic opioid ad-
ministration can also decrease extracellular levels of adenosine
and impair A1AR signaling in the brainstem (Nelson et al., 2009).
Attempts at targeting the adenosine system in search for better
analgesics have focused on A1AR and A2ARs but with limited
success because of negative side-effect profiles (Zylka, 2011; Boi-
son, 2013). Other attempts aimed at increasing endogenous
adenosine with recombinant ectonucleotidases (Sowa et al.,
2010) or adenosine kinase inhibitors (Kowaluk et al., 2000) have
also proved disappointing. Attention has now shifted to A3AR as
a possible cellular target for developing novel analgesics (Little
et al., 2015). A3ARs are expressed throughout the CNS in neu-
rons, astrocytes, and microglia, and their expression is upregu-
lated by inflammatory cytokines (Abbracchio et al., 1997; Lopes
et al., 2003). Importantly, these receptors are expressed in critical
pain signaling areas such as the spinal dorsal horn and the rostral
ventral medulla (Little et al., 2015), as well as in the reward path-
ways of the VTA and ventral striatum (D.S., unpublished obser-
vations). Small-molecule A3AR agonists that are potent, selective,
and orally bioavailable (e.g., IB-MECA [N6-(3-iodobenzyl)-
adenosine-5-N-methyl-uronamide] and MRS5698 [(1S,2R,
3S,4R,5S)-4-[6-[[(3-chlorophenyl)methyl]amino]-2-[2-(3,4-di-
fluorophenyl)ethynyl]-9H-purin-9-yl]-2,3-dihydroxy-N-met-
hylbicyclo[3.1.0]hexane-1-carboxamide]) have been developed
(Jacobson, 1998; Tosh et al., 2012) and tested in Phase II/III
clinical trials for the treatment of cancer and various autoim-
mune disorders. These trials have reported favorable safety pro-
files (Fishman et al., 2002; Silverman et al., 2008; Stemmer et al.,
2013). Moreover, a recent study by Little et al., (2015) found that
selective A3AR agonists are potent, stand-alone agents that effec-
tively attenuate chronic neuropathic pain without disrupting
normal nociceptive processing. Tolerance to the analgesic effects
of these novel A3AR agonists also did not develop, and their use
did not produce inherent reward. Thus, A3AR appears to be a
promising therapeutic target for developing novel analgesics that
may complement, or be used as pharmacological substitutes of,
traditional opioid therapy.
Sex, opioids, pain…and microglia
Neurons were considered the principal cell types targeted by opi-
oid analgesics. This neuron-centric view was supported by evi-
dence that repeated opioid exposure alters the fundamental
properties of neurons and their circuits within the CNS and PNS
and that this altered neuronal output is implicated causally in
opioid tolerance, hyperalgesia, and dependence (Guitart and
Nestler, 1989; Christie, 1991). However, the vast majority of cells
within the nervous systemare not neurons but rather glia (Banati,
2003). It is estimated that glia make up 70–90% of cells, with
microglia comprising 10% of the total glial population in the
adult CNS (Kreutzberg, 1996; Aguzzi et al., 2013; Kettenmann et
al., 2013). Conventionally regarded as macrophages, microglia
were relegated to being passive bystanders that subserve immune
and supportive roles for neurons. This perception of microglia
has changed radically in the past decade, and it is now apparent
that microglia play an active and direct role in a variety of pro-
cesses, including synaptic remodeling, neuronal excitability, and
neurotransmission (Tremblay et al., 2010; Blank et al., 2014;
Salter and Beggs, 2014). The role ofmicroglia as cellular detectors
and effectors of injury, infection, or disease has also gained con-
siderable traction (Trang et al., 2012; Ji et al., 2013). In this re-
spect, the importance of microglia in the sequelae of neuropathic
pain is well established, and it is known that injury to a nerve
instigates a stereotypical series of change in microglial morphol-
ogy, gene expression, function, and number (Hanisch and
Kettenmann, 2007; Kettenmann et al., 2011; Trang and Salter,
2012). These changes are also engaged by morphine; in response
to chronicmorphine treatment,microglia transform froma ram-
ified (“resting”) to amoeboid (“activated”) state and upregulate
expression of the cell-surface markers CD11b and ionized
calcium-binding adaptor-1 (Ferrini et al., 2013; Schwarz et al.,
2013; Mattioli et al., 2014). These phenotypic changes, triggered
by opioid treatment or nerve injury, are the cellular and molecu-
lar signatures ofmicroglial “activation.” Additional evidence that
microglia are important opioid targets comes from reports that
they express  and  receptors (Chao et al., 1997; Mika et al.,
2014). Activation of opioid receptors on microglia induces the
release of a myriad of chemokines, cytokines, and neurotrophic
factors (Coller andHutchinson, 2012;Me´lik Parsadaniantz et al.,
2015). Treatments with nonspecific glial inhibitors (e.g., mino-
cycline, fluorocitrate, or propentofylline) block the opioid-
induced release of these signaling molecules and suppress the
increase inmicroglial reactivity (Watkins andMaier, 2003; Cui et
al., 2008; Horvath and DeLeo, 2009). The cellular effects of glial
inhibitors translate into a reduction in morphine analgesic toler-
ance, an attenuation of the paradoxical increase in pain sensitiv-
ity, and a decrease in dependence (Horvath et al., 2010; Fukagawa
et al., 2013). Glial inhibitors have also been found to alleviate pain
hypersensitivity after peripheral nerve injury (Raghavendra et al.,
2003; Guasti et al., 2009; Grace et al., 2014). Thus, the most par-
simonious conclusion is that glia, in particular microglia, play an
essential role in both neuropathic pain and the negative effects
associated with long-term opioid use.
This conclusion, which is derived from experiments con-
ducted almost exclusively on male rodents, has gained wide
acceptance and is perpetuated by the discovery of an ever-
increasing number ofmicroglial mechanisms being implicated in
chronic pain. However, a study by Sorge et al. (2011) challenged
the totality of such a conclusion as it relates to chronic pain
mechanisms in male versus female mice. In this study, they re-
ported that involvement of spinal TLR4 in mechanical allodynia
was male specific. Because TLR4 in the CNS is expressed primar-
ily on microglia, this initial observation hinted at the possible
existence of a divergent microglial pain signaling mechanism be-
ing sexually dimorphic. In amore recent study, Sorge et al. (2015)
demonstrated that intrathecal administration of glial inhibitors
prevented and reversed mechanical allodynia caused by periph-
eral nerve injury in male, but not in female, mice. Allodynia in
female mice was also resistant to selective ablation of spinal mi-
croglia by saporin toxin conjugated to macrophage antigen
complex-1 and occurred independent of purinergic P2X4 recep-
tor (P2X4R)-mediated release of brain-derived neurotrophic fac-
tor (BDNF), which is a core microglia pain signaling pathway
identified previously in male rodents (see below) (Coull et al.,
2005; Sorge et al., 2015). Together, these findings indicate that
microglia are not sufficient for pain hypersensitivity in female
mice. Instead, it appears that adaptive immune cells, likely
T-lymphocytes, critically mediate pain hypersensitivity in female
mice. This sexual dimorphism in mice is consistent with a clear
gender bias in humans toward women being the majority of
chronic pain patients (Mogil, 2012).
Although there is also evidence for sex differences in analgesic
response to opioids and in susceptibility for opioid abuse in hu-
mans and rodents (Mogil, 2012; Lee and Ho, 2013), it remains to
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be shown whether these differences involve divergent microglial
signaling mechanisms. Therefore, we will proceed to discuss a
novel microglial signaling mechanism discovered to be essential
in the paradoxical pain produced by morphine, with the explicit
caveat that these discoveries were made using male rodent sub-
jects. In this context, a recent study by Ferrini et al. (2013) exam-
ined the relationship between morphine analgesic tolerance and
morphine-induced hyperalgesia; the prevailing viewwas that tol-
erance andhyperalgesia reflect a single underlyingmechanism. In
this study, the authors found that morphine acting on  recep-
tors drives increased expression of P2X4R on microglia and that
blocking P2X4R or specifically ablating spinal microglia reversed
morphine-induced hyperalgesia without affecting tolerance.
Furthermore, morphine treatment caused a P2X4R-dependent
release of BDNF frommicroglia: the release of BDNF signaled to
downregulate the Cl cotransporter KCC2 on spinal lamina I
neurons, leading to a dysregulation of Cl homeostasis (Fig. 2).
Restoring Cl homeostasis by genetically deleting BDNF from
microglia reversed morphine-induced hyperalgesia but had no
effect on analgesic tolerance. Collectively, these findings dissoci-
ate morphine-induced hyperalgesia from analgesic tolerance and
suggest that interfering with key nodes in the microglia-to-
neuron P2X4R–BDNF–KCC2 pathway suppresses hyperalgesia
without affectingmorphine analgesia. It is important to note that
this pathwaywas first causally implicated inmechanical allodynia
caused by peripheral nerve injury (Tsuda et al., 2003; Coull et al.,
2005). Thus, the P2X4R–BDNF–KCC2 pathway is a common
microglial mechanism that underlies the hyperalgesic effects of
morphine and neuropathic pain (Tsuda et al., 2003; Coull et al.,
2005; Keller et al., 2007; Ulmann et al., 2008; Trang et al., 2009;
Ferrini et al., 2013). Although this pathway is amajor component
of the functional alterations in the spinal dorsal horn that results
in ongoing pain after chronic morphine treatment or peripheral
nerve injury, it is one of several microglial mechanisms thought
to contribute to these conditions (Watkins et al., 2001; Clark et
al., 2007; Ji, 2010; Zhuo et al., 2011; Berta et al., 2014). How each
of these mechanisms converges or diverges and whether sexual
dimorphism has an effect on their relative importance has yet to
be determined.
Opioid reward and its modulation by chronic opioids
and pain
Opioids are potent analgesics that produce both positive and
negative reinforcement. The positive reinforcing effects (eupho-
ria, hedonism, or reward) resulting from opioid use are associ-
ated strongly with their high potential for abuse, whereas the
negative reinforcing effects of opioid use arise from the potent
alleviation of the negative sensory and affective/emotional as-
pects of pain. A canonical neurotransmitter associated strongly
with altered mood states and the positive and negative reinforc-
ing effects of opioids is dopamine. The mesocorticolimbic sys-
tem, which includes the VTA and the nucleus accumbens (NAc,
part of the ventral striatum) is responsible for the expression of
motivated behaviors, arousal, and reinforcement learning pro-
duced by natural (e.g., sex, food) and drug-rewarding stimuli, as
well as aversion-based behaviors (Wise, 1989; Koob and LeMoal,
2005; Fields et al., 2007).
Dopaminergic neurons within the VTA are regulated by
GABAergic tone via either intrinsic or synaptic input. Activation
of opioid receptors expressed on intrinsic and synaptic projection
GABAergic neurons causes an increase in dopamine release via
disinhibition of the GABA tone. This opioid control of dopamine
neurons is gated primarily by opioid receptors expressed on
GABAergic terminals arising from the rostromedial tegmental
nucleus (RMTg) rather than GABA intrinsic neurons or the NAc
medium spiny neurons (Matsui et al., 2014). Additionally, sepa-
rate GABA afferents are affected in the development of tolerance
(RMTg) andwithdrawal (NAc), whereas VTAGABAergic intrin-
sic neurons were not modulated by either state (Matsui et al.,
2014). Nevertheless, the VTA is critical for opioid reward because
rodents will self-administer intra-VTA morphine, and condi-
tioned place preference to systemically administeredmorphine is
blocked by intra-VTA administration of  receptor antagonists
(David et al., 2008; Mazei-Robison and Nestler, 2012; Fields and
Margolis, 2015). These data together suggest that opioid recep-
tors in the VTA are “sufficient” but not “necessary” for opioid-
induced reward.
Recent studies suggest that VTA dopamine neurons are orga-
nized topographically according to output projection targets and
that such organization may be relevant to their activation by
appetitive and aversive stimuli (Lammel et al., 2012). Whether
opioidsmodulate specific VTA dopaminergic output projections
remains an important unresolved question. Similar to the VTA,
the NAc shows topographical organization with hedonic and
aversive “hot and cold spots” (McCutcheon et al., 2012; Berridge
and Kringelbach, 2013). The rostrodorsal quadrant of the medial
NAc shell contains a specialized opioid hedonic hotspot that me-
diates an increase in “liking” after  receptor activation. In con-
trast, a distinct suppressive cold spot in the caudal half of the shell
was identified in which opioid stimulation reduced sucrose pos-
Figure 2. Microglial-mediated disruption of chloride homeostasis in spinal lamina I neurons gates morphine hyperalgesia. In response to chronic morphine treatment, microglia residing in
the spinal cord adopt a reactive state characterized by receptor-dependent upregulation of P2X4R expression. Activation of P2X4R causes the release of BDNF, which signals to downregulate
the potassium-chloride cotransport KCC2, resulting in a dysregulation of chloride homeostasis in spinal lamina I pain signaling neurons. The P2X4R–BDNF–KCC2 pathway is not only critical for the
paradoxical hyperalgesic effect of morphine but also for pain hypersensitivity after peripheral nerve injury.
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itive liking reactions (Castro and Berridge, 2014). These results
demonstrate the anatomical heterogeneity of the NAc and the
importance of this region in opioid reward.
Reward produced by intra-VTA administration of opioids is
blunted or absent after chronic opioid administration. This effect
correlates with an increase in VTA GABAergic currents (Madha-
van et al., 2010) and an increase in the frequency of spontaneous
miniature IPSCs within the VTA dopaminergic neurons (Bonci
and Williams, 1997). This is consistent with the report that elec-
trically evoked VTA dopamine output to the NAc is decreased
24 h after cessation of chronic morphine (Mazei-Robison et al.,
2011). Importantly, repeated drug exposure causes a decrease in
the rewarding effect of the drug (reward tolerance), and this leads
to an escalation of drug intake, as seen in humans (O’Brien,
1997). As noted previously, similarities exist between chronic
opioid use and chronic pain. This is also true in the mesolimbic
system. Similar to dependent states, morphine-stimulated dopa-
mine release is attenuated in animals with chronic pain (Ozaki et
al., 2002). Taylor et al. (2015b) replicated this finding and also
reported that cocaine-induced, but not amphetamine-induced,
dopamine release was attenuated in chronic pain animals. The
impaired mesolimbic dopamine response in chronic pain is sup-
ported by a recent human functional magnetic resonance imag-
ing study that found dramatically reduced reward-stimulated
activity in the VTA of fibromyalgia patients (Loggia et al., 2014).
Although the mechanisms underlying the neuronal plastic
changes associated with the development and the progression of
drug addiction remain unknown, BDNF is implicated in incen-
tive motivation that drives drug-seeking behavior. BDNF is a
critical modulator of VTA dopamine neuronal activity in opioid-
dependent animals (Vargas-Perez et al., 2009, 2014; Koo et al.,
2012). Furthermore, intra-VTA BDNF can produce an opioid-
Figure3. Model ofmicroglial-mediatedaltered reward circuitry. As a consequenceof chronic opioid exposureor chronic pain,microglial activationoccurs inmanyareas of theCNS, includingbrain
regions involved in reward such as the VTA. It is hypothesized that gliosis triggers a reorganization of reward circuitry such that microglia change EGABA in GABAergic neurons within the VTA. A, In
the naive state, these neurons tonically inhibit mesolimbic dopaminergic neurons projecting to the NAc. B, In chronic pain states, activatedmicroglia release BDNF. This in turn causes disruption of
EGABA via downregulationof theK
/Cl transporter KCC2protein levels andactivity. The loss of KCC2 causes adisruptionof Clhomeostasis inGABAergic neurons, resulting in theseneurons being
moredepolarized. Consequently, activationofGABAA receptors on theseGABAergic neurons results in their depolarization rather thanhyperpolarizationbecause of anet inward anion (Cl
/HCO3
 )
current (that is normally outward). An increase in the excitability of GABAergic neurons results in an increase in GABA release and augmentation of the inhibitory tone on dopaminergic neurons,
leading to less dopamine release in the NAc. DA, Dopamine.
13884 • J. Neurosci., October 14, 2015 • 35(41):13879–13888 Trang et al. • Pain and Opioids
dependent-like state in naive animals (Laviolette and van der
Kooy, 2001; Laviolette et al., 2002, 2004; Vargas-Perez et al., 2009,
2014). BDNF can cause GABAA function in VTA GABAergic
interneurons to shift from inhibition to excitation (Fig. 3). There
is evidence in other systems that BDNF can change GABAergic
excitability via downregulation of KCC2 (Coull et al., 2005; Fer-
rini et al., 2013; Gagnon et al., 2013; Ting-A-Kee et al., 2013). Like
other areas of the brain, downregulation of KCC2 in VTA
GABAA-expressing neurons results in an increase in their excit-
ability. It was identified recently that both chronic pain and
chronic administration of morphine causes a loss in the expres-
sion of KCC2 in VTAGABAergic neurons that results in a greater
tonic inhibition on dopamine neurons (Taylor et al., 2015a,b).
The mechanism of how chronic administration of opioids or
chronic painmodulates reward circuitry within the VTA remains
unresolved, although recent evidence demonstrates that micro-
glial activation contributes to changes in opioid reward (Taylor et
al., 2015a,b). Chronic morphine administration results in signif-
icant gliosis in the VTA andNAc (Narita et al., 2006; Hutchinson
et al., 2009; Schwarz et al., 2013). Similarly, chronic pain in the
absence of opioid medication use also causes microglial activa-
tion in reward circuitry (Taylor et al., 2015b). Inhibitors of both
BDNF and microglia recover the loss of KCC2 function and re-
stores morphine- and cocaine-evoked dopamine release. The
functional behavioral consequence of this change in VTA
GABAergic tone was evidenced by the loss of reward-related be-
haviors dependent on mesolimbic dopamine release in the NAc.
Hence, intra-NAc cocaine and intra-VTA opioid conditioned
place preference was blunted in chronic pain animals. Again,
microglial inhibitors recovered reward in chronic pain animals
but had no effect in pain-naive animals. Together, such findings
suggest thatmicroglial activation results in dysfunction of reward
reliant onmesolimbic dopamine during ongoing chronic pain or
opioid-dependent states. Howmicroglia become activated in the
brain after a peripheral nerve injury remains unresolved, and it is
unknown whether any of these effects are reversible.
Summary
In 1680, Thomas Sydenham espoused that “Among the remedies
which it has pleased almighty God to give to man to relieve his
sufferings, none is so universal and so efficacious as opium.”
Indeed, the potent pain-relieving effects of opioids are un-
matched, but it is nowunderstood that alongwith the “good” can
come the “bad”: analgesic tolerance, hyperalgesia, dependence,
and reward are recognized as potential adverse consequences of
opioid use. Attempts to negate the adverse effects of opioids and
provide relief to those in pain have been directed mostly at neu-
ronal targets but with only limited success. These strategies were
predicated on the misconception that neurons are the sole and
principal targets of opioid action. On the contrary, converging
lines of evidence indicate that opioids engage a complex constel-
lation of cellular andmolecular processes, throughwhich a diver-
sity of cell types interact to produce the negative effects associated
with opioid use. Glia–neuron interactions are key to establishing
and maintaining altered responsiveness of the CNS to long-term
opioid treatment, and, in particular, it is the influence of micro-
glia that is critical. The conceptual shift frommicroglia as passive
bystanders to active effectors of opioid analgesia is amajor break-
through that has reoriented the search for new therapeutic tar-
gets. One potential target highlighted in this review is the
microglia-to-neuron P2X4R–BDNF–KCC2 pathway, which
serves an overlapping role in the pain hypersensitivity caused by
repeated morphine treatment and by peripheral nerve injury.
This pathway is also important in altering reward circuitry in
chronic pain states. Moreover, adenosine and PDGFR- signal-
ing have emerged as a common mechanism in morphine toler-
ance and neuropathic pain. The commonalities in mechanisms
between opioid tolerance, opioid-induced hyperalgesia, and neu-
ropathic pain provide an exciting opportunity to bridge thera-
peutic strategies aimed at improving the utility of opioids for
treating pain. However, the design of any therapeutic approach
must take into account potentialmechanistic differences between
males and females given the recent evidence for sexual dimor-
phism in the role ofmicroglia in neuropathic pain. The challenge,
from the perspective of pain management, is to exploit this new
knowledge to enhance the utility of opioids in treating chronic
pain without stifling the potent analgesic properties of this im-
portant class of drugs.
References
Abbracchio MP, Rainaldi G, Giammarioli AM, Ceruti S, Brambilla R, Cat-
tabeni F, Barbieri D, Franceschi C, Jacobson KA,MalorniW (1997) The
A3 adenosine receptor mediates cell spreading, reorganization of actin
cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma
cells. Biochem Biophys Res Commun 241:297–304. CrossRef Medline
Aguzzi A, Barres BA, Bennett ML (2013) Microglia: scapegoat, saboteur, or
something else? Science 339:156–161. CrossRef Medline
Ahlijanian MK, Takemori AE (1985) Effects of ()-N6-(R-phenylisopropyl)-
adenosine (PIA) and caffeine on nociception andmorphine-induced analgesia,
tolerance and dependence in mice. Eur J Pharmacol 112:171–179. CrossRef
Medline
Banati RB (2003) Neuropathological imaging: in vivo detection of glial ac-
tivation as a measure of disease and adaptive change in the brain. Br Med
Bull 65:121–131. CrossRef Medline
Beggs S, Trang T, Salter MW (2012) P2X4R microglia drive neuropathic
pain. Nat Neurosci 15:1068–1073. CrossRef Medline
Belcheva MM, Szu`cs M, Wang D, Sadee W, Coscia CJ (2001) mu-Opioid
receptor-mediated ERK activation involves calmodulin-dependent epi-
dermal growth factor receptor transactivation. J Biol Chem 276:33847–
33853. CrossRef Medline
Berridge KC, Kringelbach ML (2013) Neuroscience of affect: brain mecha-
nisms of pleasure and displeasure. Curr Opin Neurobiol 23:294–303.
CrossRef Medline
Berta T, Park CK, Xu ZZ, Xie RG, Liu T, Lu¨ N, Liu YC, Ji RR (2014) Extra-
cellular caspase-6 drives murine inflammatory pain viamicroglial TNF-
secretion. J Clin Invest 124:1173–1186. CrossRef Medline
Blackburn MR, Kellems RE (1996) Regulation and function of adenosine
deaminase inmice. ProgNucleic Acid ResMol Biol 55:195–226. CrossRef
Medline
Blank T, Goldmann T, Prinz M (2014) Microglia fuel the learning brain.
Trends Immunol 35:139–140. CrossRef Medline
Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ
(2001) Chronic pain in Australia: a prevalence study. Pain 89:127–134.
CrossRef Medline
Boison D (2013) Role of adenosine in status epilepticus: a potential new
target? Epilepsia 54 [Suppl 6]:20–22.
Boison D, Chen JF, Fredholm BB (2010) Adenosine signaling and function
in glial cells. Cell Death Differ 17:1071–1082. CrossRef Medline
Bonan CD (2012) Ectonucleotidases and nucleotide/nucleoside transport-
ers as pharmacological targets for neurological disorders. CNS Neurol
Disord Drug Targets 11:739–750. CrossRef Medline
Bonci A, Williams JT (1996) A common mechanism mediates long-term
changes in synaptic transmission after chronic cocaine and morphine.
Neuron 16:631–639. CrossRef Medline
Bonci A, Williams JT (1997) Increased probability of GABA release during
withdrawal from morphine. J Neurosci 17:796–803. Medline
Bourinet E, Altier C, Hildebrand ME, Trang T, Salter MW, Zamponi GW
(2014) Calcium-permeable ion channels in pain signaling. Physiol Rev
94:81–140. CrossRef Medline
Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D (2006) Survey of
chronic pain in Europe: prevalence, impact on daily life, and treatment.
Eur J Pain 10:287–333. CrossRef Medline
Cahill CM,TaylorAM,CookC,OngE,Moro´n JA, EvansCJ (2014) Does the
Trang et al. • Pain and Opioids J. Neurosci., October 14, 2015 • 35(41):13879–13888 • 13885
kappa opioid receptor system contribute to pain aversion? Front Pharma-
col 5:253. Medline
Castro DC, Berridge KC (2014) Opioid hedonic hotspot in nucleus accum-
bens shell: mu, delta, and kappa maps for enhancement of sweetness
“liking” and “wanting.” J Neurosci 34:4239–4250. CrossRef
Chao CC, Hu S, Shark KB, Sheng WS, Gekker G, Peterson PK (1997) Acti-
vation of mu opioid receptors inhibits microglial cell chemotaxis. J Phar-
macol Exp Ther 281:998–1004. Medline
Christie MJ (1991) Mechanisms of opioid actions on neurons of the locus
coeruleus. Prog Brain Res 88:197–205. CrossRef Medline
Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, Marchand F, Dehvari M,
Wotherspoon G, Winter J, Ullah J, Bevan S, Malcangio M (2007) Inhi-
bition of spinalmicroglial cathepsin S for the reversal of neuropathic pain.
Proc Natl Acad Sci U S A 104:10655–10660. CrossRef Medline
Coller JK,HutchinsonMR (2012) Implications of central immune signaling
caused by drugs of abuse: mechanisms, mediators and new therapeutic
approaches for prediction and treatment of drug dependence. Pharmacol
Ther 134:219–245. CrossRef Medline
ComptonWM,VolkowND (2006) Abuse of prescription drugs and the risk
of addiction. Drug Alcohol Depend 83 [Suppl 1]:S4–S7. CrossRef
Contreras E, Germany A, VillarM (1990) Effects of some adenosine analogs
on morphine-induced analgesia and tolerance. Gen Pharmacol 21:763–
767. CrossRef Medline
Convertino M, Samoshkin A, Gauthier J, Gold MS, Maixner W, Dokholyan
NV, Diatchenko L (2015) -Opioid receptor 6-transmembrane iso-
form: A potential therapeutic target for new effective opioids. Prog Neu-
ropsychopharmacol Biol Psychiatry 62:61–67. CrossRef Medline
Coull JA, Beggs S, Boudreau D, Boivin D, TsudaM, Inoue K, Gravel C, Salter
MW, De Koninck Y (2005) BDNF from microglia causes the shift in
neuronal anion gradient underlying neuropathic pain. Nature 438:1017–
1021. CrossRef Medline
Cui Y, LiaoXX, LiuW,GuoRX,WuZZ, ZhaoCM,Chen PX, Feng JQ (2008)
A novel role of minocycline: attenuating morphine antinociceptive toler-
ance by inhibition of p38 MAPK in the activated spinal microglia. Brain
Behav Immun 22:114–123. CrossRef Medline
Cunha RA (2001) Adenosine as a neuromodulator and as a homeostatic
regulator in the nervous system: different roles, different sources and
different receptors. Neurochem Int 38:107–125. CrossRef Medline
David V, Matifas A, Gavello-Baudy S, Decorte L, Kieffer BL, Cazala P (2008)
Brain regional Fos expression elicited by the activation of mu- but not
delta-opioid receptors of the ventral tegmental area: evidence for an im-
plication of the ventral thalamus in opiate reward. Neuropsychopharma-
cology 33:1746–1759. CrossRef Medline
Donica CL, Cui Y, Shi S, Gutstein HB (2014) Platelet-derived growth factor
receptor- antagonism restores morphine analgesic potency against neu-
ropathic pain. PLoS One 9:e97105. CrossRef Medline
Eisenach JC, Hood DD, Curry R, Sawynok J, Yaksh TL, Li X (2004) Intra-
thecal but not intravenous opioids release adenosine from the spinal cord.
J Pain 5:64–68. CrossRef Medline
Feng Y, He X, Yang Y, Chao D, Lazarus LH, Xia Y (2012) Current research
on opioid receptor function. Curr Drug Targets 13:230–246. CrossRef
Medline
Ferrini F, Trang T, Mattioli TA, Laffray S, Del’Guidice T, Lorenzo LE, Cas-
tonguay A, Doyon N, Zhang W, Godin AG, Mohr D, Beggs S, Vandal K,
Beaulieu JM, Cahill CM, Salter MW, De Koninck Y (2013) Morphine
hyperalgesia gated through microglia-mediated disruption of neuronal
Cl homeostasis. Nat Neurosci 16:183–192. CrossRef Medline
Fields H (2004) State-dependent opioid control of pain. Nat Rev Neurosci
5:565–575. CrossRef Medline
Fields HL, Margolis EB (2015) Understanding opioid reward. Trends Neu-
rosci 38:217–225. CrossRef Medline
Fields HL, Hjelmstad GO, Margolis EB, Nicola SM (2007) Ventral tegmen-
tal area neurons in learned appetitive behavior and positive reinforce-
ment. Annu Rev Neurosci 30:289–316. CrossRef Medline
Fioravanti B, Vanderah TW (2008) The ORL-1 receptor system: are there
opportunities for antagonists in pain therapy? Curr Top Med Chem
8:1442–1451. CrossRef Medline
FishmanP,Bar-YehudaS,MadiL,CohnI (2002) A3adenosine receptor as a target
for cancer therapy. AnticancerDrugs 13:437–443.CrossRefMedline
Fredholm BB, Chen JF, Masino SA, Vaugeois JM (2005) Actions of adeno-
sine at its receptors in the CNS: insights from knockouts and drugs. Annu
Rev Pharmacol Toxicol 45:385–412. CrossRef Medline
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Mu¨ller CE (2011) In-
ternational Union of Basic and Clinical Pharmacology. LXXXI. Nomen-
clature and classification of adenosine receptors—an update. Pharmacol
Rev 63:1–34. CrossRef Medline
Fukagawa H, Koyama T, Kakuyama M, Fukuda K (2013) Microglial ac-
tivation involved in morphine tolerance is not mediated by toll-like
receptor 4. J Anesth 27:93–97. CrossRef Medline
Gagnon M, Bergeron MJ, Lavertu G, Castonguay A, Tripathy S, Bonin RP,
Perez-Sanchez J, Boudreau D, Wang B, Dumas L, Valade I, Bachand K,
Jacob-Wagner M, Tardif C, Kianicka I, Isenring P, Attardo G, Coull JA,
De Koninck Y (2013) Chloride extrusion enhancers as novel therapeu-
tics for neurological diseases. Nat Med 19:1524–1528. CrossRef Medline
Gamse R, Holzer P, Lembeck F (1979) Indirect evidence for presynaptic
location of opiate receptors on chemosensitive primary sensory neurones.
Naunyn Schmiedebergs Arch Pharmacol 308:281–285. CrossRefMedline
Germany A, VillarM, Quijada L, Contreras E (1990) Influence of adenosine
analogs on morphine tolerance and dependence in mice. Cell Mol Biol
36:409–414. Medline
Gomes T, Mamdani MM, Paterson JM, Dhalla IA, Juurlink DN (2014)
Trends in high-dose opioid prescribing in Canada. Can Fam Physician
60:826–832. Medline
Gouarde`res C, Cros J, Quirion R (1985) Autoradiographic localization of
mu, delta and kappa opioid receptor binding sites in rat and guinea pig
spinal cord. Neuropeptides 6:331–342. CrossRef Medline
Grace PM,HutchinsonMR,Maier SF,Watkins LR (2014) Pathological pain
and the neuroimmune interface. Nat Rev Immunol 14:217–231. CrossRef
Medline
Guasti L, Richardson D, Jhaveri M, Eldeeb K, Barrett D, Elphick MR, Alex-
ander SP, Kendall D,Michael GJ, ChapmanV (2009) Minocycline treat-
ment inhibits microglial activation and alters spinal levels of
endocannabinoids in a rat model of neuropathic pain. Mol Pain 5:35.
CrossRef Medline
Guitart X, Nestler EJ (1989) Identification of morphine- and cyclic AMP-
regulated phosphoproteins (MARPPs) in the locus coeruleus and other
regions of rat brain: regulation by acute and chronicmorphine. JNeurosci
9:4371–4387. Medline
Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile
effector cells in the normal and pathologic brain. Nat Neurosci 10:1387–
1394. CrossRef Medline
Ho IK, Loh HH, Way EL (1973a) Effects of cyclic 3,5-adenosine mono-
phosphate onmorphine tolerance and physical dependence. J Pharmacol
Exp Ther 185:347–357. Medline
Ho IK, Loh HH, Way EL (1973b) Cyclic adenosine monophosphate antag-
onism of morphine analgesia. J Pharmacol Exp Ther 185:336–346.
Medline
Horvath RJ, DeLeo JA (2009) Morphine enhances microglial migration
throughmodulation of P2X4 receptor signaling. J Neurosci 29:998–1005.
CrossRef Medline
Horvath RJ, Romero-Sandoval EA, De Leo JA (2010) Inhibition of micro-
glial P2X4 receptors attenuates morphine tolerance, Iba1, GFAP and mu
opioid receptor protein expression while enhancing perivascular micro-
glial ED2. Pain 150:401–413. CrossRef Medline
HutchinsonMR, Lewis SS, Coats BD, SkybaDA,CrysdaleNY, Berkelhammer
DL, Brzeski A, Northcutt A, Vietz CM, Judd CM, Maier SF, Watkins LR,
Johnson KW (2009) Reduction of opioid withdrawal and potentiation
of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav
Immun 23:240–250. CrossRef Medline
Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX,
Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE,
Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice
KC, Watkins LR (2010) Evidence that opioids may have toll-like recep-
tor 4 andMD-2 effects. Brain Behav Immun 24:83–95. CrossRef Medline
Jacobsen JH, Watkins LR, Hutchinson MR (2014) Discovery of a novel site
of opioid action at the innate immune pattern-recognition receptor TLR4
and its role in addiction. Int Rev Neurobiol 118:129–163. CrossRef
Medline
Jacobson KA (1998) Adenosine A3 receptors: novel ligands and paradoxical
effects. Trends Pharmacol Sci 19:184–191. CrossRef Medline
Ji RR (2010) Targeting microglial purinergic signaling to improve mor-
phine analgesia. Pain 150:377–378. CrossRef Medline
Ji RR, Berta T, NedergaardM (2013) Glia and pain: is chronic pain a gliopa-
thy? Pain 154 [Suppl 1]:S10–S28. CrossRef
13886 • J. Neurosci., October 14, 2015 • 35(41):13879–13888 Trang et al. • Pain and Opioids
Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH (2010) The prev-
alence of chronic pain inUnited States adults: results of an Internet-based
survey. J Pain 11:1230–1239. CrossRef Medline
Keller AF, Beggs S, Salter MW, De Koninck Y (2007) Transformation of the
output of spinal lamina I neurons after nerve injury and microglia stim-
ulation underlying neuropathic pain. Mol Pain 3:27. CrossRef Medline
Kemp T, Spike RC, Watt C, Todd AJ (1996) The mu-opioid receptor
(MOR1) is mainly restricted to neurons that do not contain GABA or
glycine in the superficial dorsal horn of the rat spinal cord. Neuroscience
75:1231–1238. CrossRef Medline
Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of
microglia. Physiol Rev 91:461–553. CrossRef Medline
Kettenmann H, Kirchhoff F, Verkhratsky A (2013) Microglia: new roles for
the synaptic stripper. Neuron 77:10–18. CrossRef Medline
King AE, Ackley MA, Cass CE, Young JD, Baldwin SA (2006) Nucleoside
transporters: from scavengers to novel therapeutic targets. Trends Phar-
macol Sci 27:416–425. CrossRef Medline
Koo JW,Mazei-RobisonMS, ChaudhuryD, Juarez B, LaPlantQ, FergusonD,
Feng J, Sun H, Scobie KN, Damez-Werno D, Crumiller M, Ohnishi YN,
Ohnishi YH, Mouzon E, Dietz DM, Lobo MK, Neve RL, Russo SJ, Han
MH, Nestler EJ (2012) BDNF is a negative modulator of morphine ac-
tion. Science 338:124–128. CrossRef Medline
Koob GF, Le Moal M (2005) Plasticity of reward neurocircuitry and the
“dark side” of drug addiction. Nat Neurosci 8:1442–1444. CrossRef
Medline
KowalukEA,MikusaJ,WismerCT,ZhuCZ,SchweitzerE,LynchJJ,LeeCH,JiangM,
Bhagwat SS, Gomtsyan A, McKie J, Cox BF, Polakowski J, Reinhart G, Will-
iams M, Jarvis MF (2000) ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-
morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective
adenosinekinaseinhibitorwithanalgesicandanti-inflammatoryproperties.II.In
vivo characterization in the rat. J Pharmacol ExpTher 295:1165–1174.Medline
Kreutzberg GW (1996) Microglia: a sensor for pathological events in the
CNS. Trends Neurosci 19:312–318. CrossRef Medline
Lammel S, Lim BK, Ran C, Huang KW, Betley MJ, Tye KM, Deisseroth K,
Malenka RC (2012) Input-specific control of reward and aversion in the
ventral tegmental area. Nature 491:212–217. CrossRef Medline
Lamotte C, Pert CB, Snyder SH (1976) Opiate receptor binding in primate
spinal cord: distribution and changes after dorsal root section. Brain Res
112:407–412. CrossRef Medline
Largent-Milnes TM, Vanderah TW (2010) Recently patented and promis-
ing ORL-1 ligands: where have we been and where are we going? Expert
Opin Ther Pat 20:291–305. CrossRef Medline
Laviolette SR, van der Kooy D (2001) GABA(A) receptors in the ventral
tegmental area control bidirectional reward signalling between dopami-
nergic and non-dopaminergic neural motivational systems. Eur J Neuro-
sci 13:1009–1015. CrossRef Medline
Laviolette SR, Nader K, van der Kooy D (2002) Motivational state deter-
mines the functional role of the mesolimbic dopamine system in the
mediation of opiate reward processes. Behav Brain Res 129:17–29.
CrossRef Medline
Laviolette SR, Gallegos RA, Henriksen SJ, van der Kooy D (2004) Opiate
state controls bi-directional reward signaling via GABAA receptors in the
ventral tegmental area. Nat Neurosci 7:160–169. CrossRef Medline
Lee CW, Ho IK (2013) Sex differences in opioid analgesia and addiction:
interactions among opioid receptors and estrogen receptors. Mol Pain
9:45. CrossRef Medline
Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine ki-
nases. Cell 141:1117–1134. CrossRef Medline
Little JW, Ford A, Symons-Liguori AM, Chen Z, Janes K, Doyle T, Xie J,
Luongo L, Tosh DK, Maione S, Bannister K, Dickenson AH, Vanderah
TW, Porreca F, Jacobson KA, Salvemini D (2015) Endogenous adeno-
sine A3 receptor activation selectively alleviates persistent pain states.
Brain 138:28–35. CrossRef Medline
Loggia ML, Berna C, Kim J, Cahalan CM, Gollub RL, Wasan AD, Harris RE,
Edwards RR, Napadow V (2014) Disrupted brain circuitry for pain-
related reward/punishment in fibromyalgia. Arthritis Rheumatol 66:203–
212. CrossRef Medline
Lopes LV, Rebola N, Pinheiro PC, Richardson PJ, Oliveira CR, Cunha RA
(2003) Adenosine A3 receptors are located in neurons of the rat hip-
pocampus. Neuroreport 14:1645–1648. CrossRef Medline
Madhavan A, Bonci A, Whistler JL (2010) Opioid-Induced GABA potenti-
ation after chronic morphine attenuates the rewarding effects of opioids
in the ventral tegmental area. J Neurosci 30:14029–14035. CrossRef
Medline
Manchikanti L, Helm Ii S, Singh V, Hirsch JA (2013) Accountable interven-
tional pain management: a collaboration among practitioners, patients,
payers, and government. Pain Physician 16:E635–E670. Medline
Mao J, Mayer DJ (2001) Spinal cord neuroplasticity following repeated opi-
oid exposure and its relation to pathological pain. Ann NY Acad Sci
933:175–184. CrossRef Medline
MarchandF, PerrettiM,McMahon SB (2005) Role of the immune system in
chronic pain. Nat Rev Neurosci 6:521–532. CrossRef Medline
Matsui A, Jarvie BC, Robinson BG, Hentges ST, Williams JT (2014) Sepa-
rate GABA afferents to dopamine neurons mediate acute action of opi-
oids, development of tolerance, and expression of withdrawal. Neuron
82:1346–1356. CrossRef Medline
Mattioli TA, Leduc-PessahH, Skelhorne-GrossG,NicolCJ,MilneB, TrangT,
Cahill CM (2014) Toll-like receptor 4 mutant and null mice retain
morphine-induced tolerance, hyperalgesia, and physical dependence.
PLoS One 9:e97361. CrossRef Medline
Mazei-RobisonMS, Nestler EJ (2012) Opiate-inducedmolecular and cellu-
lar plasticity of ventral tegmental area and locus coeruleus catecholamine
neurons. Cold Spring Harb Perspect Med 2:a012070. CrossRef Medline
Mazei-Robison MS, Koo JW, Friedman AK, Lansink CS, Robison AJ, Vinish
M, Krishnan V, Kim S, Siuta MA, Galli A, Niswender KD, Appasani R,
Horvath MC, Neve RL, Worley PF, Snyder SH, Hurd YL, Cheer JF, Han
MH, Russo SJ, Nestler EJ (2011) Role formTOR signaling and neuronal
activity in morphine-induced adaptations in ventral tegmental area do-
pamine neurons. Neuron 72:977–990. CrossRef Medline
McCutcheon JE, Ebner SR, Loriaux AL, Roitman MF (2012) Encoding of
aversion by dopamine and the nucleus accumbens. Front Neurosci 6:137.
CrossRef Medline
Me´lik Parsadaniantz S, Rivat C, Roste`ne W, Re´aux-Le Goazigo A (2015)
Opioid and chemokine receptor crosstalk: a promising target for pain
therapy? Nat Rev Neurosci 16:69–78. CrossRef Medline
Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, But-
our JL, Guillemot JC, Ferrara P,Monsarrat B (1995) Isolation and struc-
ture of the endogenous agonist of opioid receptor-like ORL1 receptor.
Nature 377:532–535. CrossRef Medline
Mika J, Popiolek-Barczyk K, Rojewska E, Makuch W, Starowicz K, Przew-
locka B (2014) Delta-opioid receptor analgesia is independent ofmicro-
glial activation in a rat model of neuropathic pain. PLoS One 9:e104420.
CrossRef Medline
Mogil JS (2012) Sex differences in pain and pain inhibition: multiple expla-
nations of a controversial phenomenon. Nat Rev Neurosci 13:859–866.
CrossRef Medline
Morris BJ, Herz A (1987) Distinct distribution of opioid receptor types in
rat lumbar spinal cord. Naunyn Schmiedebergs Arch Pharmacol 336:
240–243. CrossRef Medline
Narita M, Yoshida T, Nakajima M, Narita M, Miyatake M, Takagi T, Yajima
Y, Suzuki T (2006) Direct evidence for spinal cord microglia in the de-
velopment of a neuropathic pain-like state in mice. J Neurochem 97:
1337–1348. CrossRef Medline
Nelson AM, Battersby AS, Baghdoyan HA, Lydic R (2009) Opioid-induced
decreases in rat brain adenosine levels are reversed by inhibiting adeno-
sine deaminase. Anesthesiology 111:1327–1333. CrossRef Medline
O’Brien CP (1997) A range of research-based pharmacotherapies for addic-
tion. Science 278:66–70. CrossRef Medline
O’Connor AB (2009) Neuropathic pain: quality-of-life impact, costs and
cost effectiveness of therapy. PharmacoEconomics 27:95–112. CrossRef
Medline
Okie S (2010) A flood of opioids, a rising tide of deaths. N Engl J Med
363:1981–1985. CrossRef Medline
Ozaki S,NaritaM,NaritaM, IinoM, Sugita J,Matsumura Y, Suzuki T (2002)
Suppression of the morphine-induced rewarding effect in the rat with
neuropathic pain: implication of the reduction in mu-opioid receptor
functions in the ventral tegmental area. J Neurochem 82:1192–1198.
CrossRef Medline
Pasternak GW, Pan YX (2013) Mu opioids and their receptors: evolution of
a concept. Pharmacol Rev 65:1257–1317. CrossRef Medline
PoonA, Sawynok J (1998) Antinociception by adenosine analogs and inhib-
itors of adenosine metabolism in an inflammatory thermal hyperalgesia
model in the rat. Pain 74:235–245. CrossRef Medline
Post C (1984) Antinociceptive effects in mice after intrathecal injection of
Trang et al. • Pain and Opioids J. Neurosci., October 14, 2015 • 35(41):13879–13888 • 13887
5-N-ethylcarboxamide adenosine. Neurosci Lett 51:325–330. CrossRef
Medline
Raghavendra V, Tanga F, Rutkowski MD, DeLeo JA (2003) Anti-
hyperalgesic and morphine-sparing actions of propentofylline following
peripheral nerve injury in rats: mechanistic implications of spinal glia and
proinflammatory cytokines. Pain 104:655–664. CrossRef Medline
Robson SC, Se´vigny J, Zimmermann H (2006) The E-NTPDase family of
ectonucleotidases: Structure function relationships and pathophysiolog-
ical significance. Purinergic Signal 2:409–430. CrossRef Medline
Salter MW, Beggs S (2014) Sublime microglia: expanding roles for the
guardians of the CNS. Cell 158:15–24. CrossRef Medline
SAMHSA (2011) SAMHSA 2011: Substance Abuse and Mental Health Ser-
vices Administration: 2011 national survey on drug use and health: sum-
mary of national findings and detailed tables. Rockville, MD: SAMHSA.
Schopflocher D, Taenzer P, Jovey R (2011) The prevalence of chronic pain
in Canada. Pain Res Manag 16:445–450. Medline
Schwarz JM, Smith SH, Bilbo SD (2013) FACS analysis of neuronal-glial
interactions in the nucleus accumbens following morphine administra-
tion. Psychopharmacology (Berl) 230:525–535. CrossRef Medline
Shoji Y, Delfs J, Williams JT (1999) Presynaptic inhibition of GABA(B)-
mediated synaptic potentials in the ventral tegmental area during mor-
phine withdrawal. J Neurosci 19:2347–2355. Medline
SilvermanMH, StrandV,Markovits D, NahirM, Reitblat T,Molad Y, Rosner
I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz P,
Rubinow A, Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns
WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB, Fishman P
(2008) Clinical evidence for utilization of the A3 adenosine receptor as a
target to treat rheumatoid arthritis: data from a phase II clinical trial.
J Rheumatol 35:41–48. Medline
Sorge RE, LaCroix-Fralish ML, Tuttle AH, Sotocinal SG, Austin JS, Ritchie J,
Chanda ML, Graham AC, Topham L, Beggs S, Salter MW, Mogil JS
(2011) Spinal cord Toll-like receptor 4 mediates inflammatory and neu-
ropathic hypersensitivity in male but not female mice. J Neurosci 31:
15450–15454. CrossRef Medline
Sorge RE,Mapplebeck JC, Rosen S, Beggs S, Taves S, Alexander JK,Martin LJ,
Austin JS, Sotocinal SG, Chen D, Yang M, Shi XQ, Huang H, Pillon NJ,
Bilan PJ, Tu Y, Klip A, Ji RR, Zhang J, Salter MW, Mogil JS (2015)
Different immune cells mediate mechanical pain hypersensitivity in male
and female mice. Nat Neurosci 18:1081–1083. CrossRef Medline
Sowa NA, Voss MK, Zylka MJ (2010) Recombinant ecto-5-nucleotidase
(CD73) has long lasting antinociceptive effects that are dependent on
adenosine A1 receptor activation. Mol Pain 6:20. CrossRef Medline
Spychala J, DattaNS, Takabayashi K,DattaM, Fox IH,Gribbin T,Mitchell BS
(1996) Cloning of human adenosine kinase cDNA: sequence similarity to
microbial ribokinases and fructokinases. Proc Natl Acad Sci U S A 93:
1232–1237. CrossRef Medline
Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-
Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer
B, Kerns WD, Fishman P (2013) CF102 for the treatment of hepatocel-
lular carcinoma: a phase I/II, open-label, dose-escalation study. Oncolo-
gist 18:25–26. CrossRef Medline
Stevens CW, Lacey CB,Miller KE, Elde RP, Seybold VS (1991) Biochemical char-
acterization and regional quantification of mu, delta and kappa opioid binding
sites in rat spinal cord. BrainRes 550:77–85.CrossRefMedline
Sweeney MI, White TD, Jhamandas KH, Sawynok J (1987) Morphine re-
leases endogenous adenosine from the spinal cord in vivo. Eur J Pharma-
col 141:169–170. CrossRef Medline
Taylor AM,Castonguay A, Taylor AJ,MurphyNP, Ghogha A, CookC, Xue L,
Olmstead MC, De Koninck Y, Evans CJ, Cahill CM (2015a) Microglia
disrupt mesolimbic reward circuitry in chronic pain. J Neurosci 35:8442–
8450. CrossRef Medline
Taylor AM, Castonguay A, Ghogha A, Vayssiere P, Pradhan AA, Xue L, Meh-
rabani S, Wu J, Levitt P, Olmstead MC, De Koninck Y, Evans CJ, Cahill
CM (2015b) Neuroimmune regulation of GABAergic neurons within
the ventral tegmental area during withdrawal from chronic morphine.
Neuropsychopharmacology. Advance online publication. Retrieved Au-
gust 19, 2015. CrossRef Medline
Thorn JA, Jarvis SM (1996) Adenosine transporters. Gen Pharmacol 27:
613–620. CrossRef Medline
Ting-A-Kee R, Vargas-Perez H, Mabey JK, Shin SI, Steffensen SC, van der
Kooy D (2013) Ventral tegmental area GABA neurons and opiate moti-
vation. Psychopharmacology (Berl) 227:697–709. CrossRef Medline
Tosh DK, Deflorian F, Phan K, Gao ZG, Wan TC, Gizewski E, Auchampach JA,
Jacobson KA (2012) Structure-guided design of A(3) adenosine receptor-
selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane
substitutions. JMedChem55:4847–4860.CrossRefMedline
Trang T, Salter MW (2012) P2X4 purinoceptor signaling in chronic pain.
Purinergic Signal 8:621–628. CrossRef Medline
Trang T, Beggs S, Wan X, Salter MW (2009) P2X4-receptor-mediated syn-
thesis and release of brain-derived neurotrophic factor in microglia is
dependent on calcium and p38-mitogen-activated protein kinase activa-
tion. J Neurosci 29:3518–3528. CrossRef Medline
Trang T, Beggs S, Salter MW (2012) ATP receptors gate microglia signaling
in neuropathic pain. Exp Neurol 234:354–361. CrossRef Medline
Tremblay ME`, Lowery RL, Majewska AK (2010) Microglial interactions
with synapses are modulated by visual experience. PLoS Biol 8:e1000527.
CrossRef Medline
TsudaM, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW,
Inoue K (2003) P2X4 receptors induced in spinal microglia gate tactile allo-
dynia after nerve injury.Nature 424:778–783.CrossRefMedline
Ulmann L, Hatcher JP, Hughes JP, Chaumont S, Green PJ, Conquet F, Buell GN,
ReeveAJ,Chessell IP,RassendrenF (2008) Up-regulationofP2X4receptors in
spinalmicroglia after peripheral nerve injurymediatesBDNFrelease andneuro-
pathic pain. JNeurosci 28:11263–11268.CrossRefMedline
Vapaatalo H, Onken D, Neuvonen PJ, Westermann E (1975) Stereospeci-
ficity in some central and circulatory effects of phenylisopropyl-
adenosine (PIA). Arzneimittelforschung 25:407–410. Medline
Vargas-Perez H, Ting-A Kee R,Walton CH, Hansen DM, Razavi R, Clarke L,
Bufalino MR, Allison DW, Steffensen SC, van der Kooy D (2009) Ven-
tral tegmental area BDNF induces an opiate-dependent-like reward state
in naive rats. Science 324:1732–1734. CrossRef Medline
Vargas-Perez H, Bahi A, Bufalino MR, Ting-A-Kee R, Maal-Bared G, Lam J,
Fahmy A, Clarke L, Blanchard JK, Larsen BR, Steffensen S, Dreyer JL, van
der Kooy D (2014) BDNF signaling in the VTA links the drug-
dependent state to drug withdrawal aversions. J Neurosci 34:7899–7909.
CrossRef Medline
Wang Y, Barker K, Shi S, Diaz M, Mo B, Gutstein HB (2012) Blockade of
PDGFR- activation eliminates morphine analgesic tolerance. Nat Med
18:385–387. CrossRef Medline
Watkins LR, Maier SF (2003) Glia: a novel drug discovery target for clinical
pain. Nat Rev Drug Discov 2:973–985. CrossRef Medline
Watkins LR, Milligan ED, Maier SF (2001) Glial activation: a driving force
for pathological pain. Trends Neurosci 24:450–455. CrossRef Medline
WenYR,TanPH,ChengJK,LiuYC, JiRR (2011) Microglia: apromising target for
treating neuropathic andpostoperative pain, andmorphine tolerance. J Formos
MedAssocTaiwanYiZhi 110:487–494.CrossRefMedline
Williams JT, Ingram SL, Henderson G, Chavkin C, von ZastrowM, Schulz S,
Koch T, Evans CJ, Christie MJ (2013) Regulation of-opioid receptors:
desensitization, phosphorylation, internalization, and tolerance. Phar-
macol Rev 65:223–254. CrossRef Medline
Wise RA (1989) Opiate reward: sites and substrates. Neurosci Biobehav Rev
13:129–133. CrossRef Medline
WuWP, Hao JX, Halldner L, Lo¨vdahl C, DeLander GE,Wiesenfeld-Hallin Z,
Fredholm BB, Xu XJ (2005) Increased nociceptive response in mice
lacking the adenosine A1 receptor. Pain 113:395–404. CrossRef Medline
ZhangY,ConklinDR,LiX,Eisenach JC (2005) Intrathecalmorphine reduces allo-
dynia after peripheral nerve injury in rats via activation of a spinal A1 adenosine
receptor. Anesthesiology 102:416–420.CrossRefMedline
Zhuo M, Wu G, Wu LJ (2011) Neuronal and microglial mechanisms of
neuropathic pain. Mol Brain 4:31. CrossRef Medline
Zieglga¨nsberger W, Bayerl H (1976) The mechanism of inhibition of neu-
ronal activity by opiates in the spinal cord of cat. Brain Res 115:111–128.
CrossRef Medline
Zylka MJ (2011) Pain-relieving prospects for adenosine receptors and ecto-
nucleotidases. Trends Mol Med 17:188–196. CrossRef Medline
13888 • J. Neurosci., October 14, 2015 • 35(41):13879–13888 Trang et al. • Pain and Opioids
